Sandoz TV Episode 18: Trailer
Find out what to expect from the newest episode of Sandoz TV.
|Global News||Sandoz Around the World||Sandoz in the Media|
FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept
Holzkirchen, October 02, 2015
Sandoz, a Novartis company and the global leader in biosimilars, announced today that the FDA has accepted its Biologics License Application (BLA) for its proposed biosimilar to Amgen’s US-licensed Enbrel® (etanercept).
Novartis launches ‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries
New York, September 24, 2015
Novartis today announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries.
Sandoz Inaugurates BioInject – a new state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria
Schaftenau, September 17, 2015
Sandoz, the generics and biosimilars business of Novartis, today officially opened its new cutting-edge biomanufacturing facility called BioInject, at Schaftenau in the Tyrolean Alps in Austria
Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States
Holzkirchen, Germany, September 03, 2015
Sandoz, a Novartis company, announced today that Zarxio™ (filgrastim-sndz) is now available in the United States.
Sandoz launches generic version of Pulmicort Respules®
Princeton, New Jersey, July 28, 2015
Sandoz today announced the US market introduction of its budesonide inhalation suspension, a generic version of Pulmicort Respules® (budesonide) inhalation suspension 1 mg strength by AstraZeneca LP.